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Human fertilization begins when spermatozoa bind to the extracellular matrix 
coating of the oocyte, known as the zona pellucida (ZP). One spermatozoan then 
penetrates this matrix and fuses with the egg cell, generating a zygote. Although 
carbohydrate sequences on the ZP have been implicated in sperm binding, the nature of 
the ligand was unknown. Here, ultrasensitive mass spectrometric analyses revealed that  
the sialyl-Lewis
x
 sequence (NeuAc2-3Gal1-4(Fuc1-3)GlcNAc), a well-known selectin 
ligand, is the most abundant terminal sequence on the N- and O-glycans of human ZP. 
Sperm-ZP binding was largely inhibited by glycoconjugates terminated with sialyl-
Lewis
x
 sequences or by antibodies directed against this sequence. Thus, the sialyl-Lewis
x
 
sequence represents the major carbohydrate ligand for human sperm-egg binding.   
 
.  
Mammalian sperm-egg binding is primarily mediated by the interaction of an egg 
binding protein (EBP) on the sperm plasma membrane with carbohydrate sequences 
expressed on glycoproteins of the egg’s zona pellucida (ZP) (1, 2). Evidence that 
carbohydrate recognition plays a major role in human gamete binding was initially obtained 
when the polysaccharide fucoidan was shown to potently block this interaction (3). Fucoidan 
also inhibited leukocyte adhesion in the vascular and lymph systems in the same 
concentration range that it blocks human sperm-ZP interactions (3, 4). The binding of 
leukocytes to endothelial cells is mediated by C-type lectins known as selectins (5, 6). 
Therefore human sperm-ZP binding was hypothesized to involve a binding specificity that 
overlaps with the selectins (7). However, the structures of the human ZP glycans have 
remained enigmatic. Furthermore, characterization of these glycans is a challenge because of 
the scarcity of human eggs and their microscopic size. We have addressed this challenge by 
employing ultra-sensitive mass spectrometric methodologies for cell and tissue glycomics (8, 
9). In N- and O-glycans, an antenna is defined as a branch emanating from a "core" structure 
(10). We have defined the structures of the majority of N-and O-glycans attached to human 
ZP and show that sialyl-Lewis
x
 is the dominant antenna sequence. This epitope is present at 
densities that are at least two orders of magnitude higher than levels of selectin-ligand 
expressed on somatic cells (11).  
ZP from 195 unfertilized human oocytes was isolated for glycan sequencing. Purity 
was assessed by proteomics analysis.  Human ZP4 was identified as the top hit in the Mascot 
search (algorithm for Mass Spectral proteomic datasets (Table S1)). The other ZP 
glycoproteins ZP1, ZP2, and ZP3 were third, fifth, and sixth, respectively, on the Mascot list. 
At second and fourth position were haptoglobin and transthyretin, which are known 
constituents in follicular fluid (12).  
The structures of the N- and O-glycans in the ZP sample were determined by 
glycomics analysis (8). Glycans were analyzed by Matrix Assisted Laser Desorption 
Ionization-Time of Flight (MALDI-TOF) Mass Spectrometry (MS) as well as by collisionally 
activated dissociation (CAD) on a MALDI-TOF-TOF instrument (MS/MS). Mixtures of N- 
and O-glycans were released from tryptic digests by peptide N-glycosidase F and reductive 
elimination, respectively, and were permethylated before MS and MS/MS analyses.  
The MALDI-TOF N-glycan fingerprint (Fig. 1) showed four families of bi-, tri- and 
tetra-antennary structures, three of which (shaded in yellow, green and pink) displayed an 
unusually high density of sialyl-Lewis
x
 antennae (NeuAc2-3Gal1-4(Fuc1-3)GlcNAc). 
All members of the latter three families were core fucosylated, and each was fully sialylated. 
Heterogeneity was confined to differences in antenna fucosylation and length. Thus, bi-
antennary glycans carried zero, one or two sialyl-Lewis
x
 antennae (m/z 2966.6, 
3140.7/3589.9/3764.0, and 3314.8/3764.0/3938.1, respectively); tri-antennary glycans carried 
zero, one, two or three sialyl-Lewis
x
 antennae (m/z 3777.1, 3951.2, 4125.2/4574.8/4748.6, 
and 4299.3/4748.6/4922.6, respectively); and tetra-antennary glycans carried zero, one, two, 
three or four sialyl-Lewis
x
 antennae (m/z 4587.5, 4761.6, 4935.8/5384.9/5559.0, 
5109.4/5559.0/5733.1 (major portion), and 5733.1 (minor portion), respectively).  
Antennae compositions were defined by CAD-MS/MS. As shown in Fig. 2 and Fig. 
S1, the most abundant fragment ions arose from cleavage of amino-sugar glycosidic bonds. 
CAD-MS/MS data from the highest molecular weight species observed in Fig. 1 (m/z 5733), 
together with its desialylated counterpart (m/z 4287.6, Fig. S2) are shown in the upper and 
lower panels, respectively, of Fig. 2. These data demonstrated that m/z 5733 was a mixture of 
tetra-antennary glycans having one extended antenna and three or four sialyl-Lewis
x
 moieties. 
The extended antenna were largely composed of the sialyl Lewis
x
-Lewis
x 
sequence 
(NeuAc2-3Gal1-4(Fuc1-3)GlcNAc1-3Gal1-4(Fuc1-3)GlcNAc), although a minority 
of glycans had only a single fucose on this antenna (right cartoon on Fig. 2, lower panel).  
Fucose was confirmed to be 3-linked in the sialyl-Lewis
x
 moiety via its diagnostic 
elimination in CAD-MS/MS experiments (Fig. 2 and Fig. S1). Linkages involving sialic acid 
were defined by MALDI analysis of an 2-3-specific neuraminidase digest of the N-glycans 
(Fig. S2), which showed that 2-6 sialylation was confined to the aforementioned fourth 
family (Fig. 1, shaded grey), that differs from the other families in having no core 
fucosylation. The human plasma glycome is characterized by the absence of core fucose plus 
high levels of 2-6 sialylation (13, 14). Therefore we concluded that this fourth glycan 
family was largely derived from the follicular fluid constituents that co-purify with ZP (Table 
S1).  
An extended sialyl-Lewis
x
-Lewis
x
 antenna, and/or its monofucosylated counterpart, 
which was identified in the m/z 5733 component (Fig. 2), was additionally found in seven 
other members of the sialyl-Lewis
x
-containing families (Fig. 1: m/z 3589.9, 3764.0, 3938.1, 
4574.8, 4748.6, 5384.9, and 5559.0). These extended sequences were firmly established by 
MS/MS analyses; examples of diagnostic fragment ions are illustrated in Fig S1 (Panel C).  
ZP N-glycans were also investigated to determine if any were sulfated, a modification 
that is known to play a key role in selectin-mediated leukocyte trafficking (15, 16). This 
study was done after desialylation by using ultrasensitive MS methodologies which have 
been optimized for sulfo-glycomics (17). Only trace levels of sulfated N-glycans were 
observed (Fig. S3). Their compositions correspond to sulfated counterparts of the core 
fucosylated glycans shown in Fig. 1.  
ZP-associated O-glycans were released from the glycopeptides recovered from the 
peptide N-glycosidase F digestion, permethylated, and analyzed by MALDI-TOF-TOF.  A 
limited number of core 1 and core 2 O-glycans were observed (Fig. S4), the latter carrying a 
single sialyl-Lewis
x
 epitope. No sulfated O-glycans were detected in the MS experiments. 
Potential O-sulfation was also investigated by using the MECA-79 antibody, which 
recognizes 6-sulfated GlcNAc on extended core 1 sequences including those terminated by 6-
sulfo sialyl-Lewis
x
. No immunoreactivity was observed (Fig. S5). 
The high density of sialyl-Lewis
x
 antennae observed on the ZP N-glycans was 
unusual.  Examples of multivalent sialyl-Lewis
x
 N-glycans are displayed in Fig. 3.  This 
epitope is highly expressed in cells and tissues associated with many human cancers (18) and 
on orosomucoid in the sera of septic shock patients (19). However, in healthy humans, where 
sialyl-Lewis
x
 plays a vital role in leukocyte trafficking, glycomics studies have suggested that 
fewer than 1% of the N-glycans carry sialyl-Lewis
x
 and none has been found to carry more 
than one sialyl-Lewis
x
 antenna (11). Another feature of the ZP N-glycome was the presence 
of extended antennae carrying an internal Lewis
x
 sequence. This structure was found in 
members of all three families and was a particularly abundant constituent of the tetra-
antennary family. This extended sialyl-Lewis
x
-Lewis
x
 sequence has previously been found on 
tumor cells, but not on normal somatic cells (20). 
The hemizona assay was employed to determine the effect of sialyl-Lewis
x
 terminated 
glycoconjugates on sperm-ZP binding (21). In this assay, nonliving human eggs were 
bisected by surgical manipulation, generating two equivalent hemispheres of ZP (hemizona). 
This test allows for an internally controlled comparison of sperm binding to a matching zona 
surface. Compared with the untreated controls, the number of sperm bound to the hemizona 
was significantly decreased after treatment with sialyl-Lewis
x
-BSA at concentrations of 0.5 
M (p= 3.3e-4), 1 M (p= 9.4e-6), 1.5 M (p =3.7e-8) and 2.0 M (p=1.2e-7). The sialyl-
Lewis
x
 oligosaccharide also significantly decreased binding at concentrations of 100 µM (p= 
1.9e-3), 200 M (p= 3.2e-5) and 500 M (p= 6.9e-9) (Fig. 4A and Fig. S6). Except for sialyl-
N-acetyllactosamine oligosaccharide at the highest concentration, no significant inhibition 
was observed with Lewis
x
, sialyl-N-acetyllactosamine oligosaccharide or BSA conjugates of 
these sequences (Fig. 4A and Fig. S6). Fluorescently-labeled sialyl-Lewis
x
-BSA was bound 
to the head of capacitated spermatozoa (Fig. 4B) but not to the hemizona (Fig. S7). In 
contrast, Lewis
x
-BSA, sialyl-N-acetyllactosamine-BSA and BSA were not bound to the 
sperm head (Fig. S8—move these panels to the SOM). These treatments did not affect the 
acrosomal status and motility of spermatozoa (Fig. S9). Consistently, anti-sialyl-Lewis
x 
(Fig. 
4C), but not anti-Lewis
x
 antibody (Fig. S5), was bound strongly to ZP and suppressed sperm-
ZP binding dose-dependently (Fig. 4D and Fig. S10). To confirm the importance of 
sialylation, the binding of fluorescence-labeled native and desialylated solubilized ZP to 
human spermatozoa was compared. Desialylation significantly reduced the binding of 
solubilized ZP to capacitated spermatozoa (Fig. 4E).  
Previous studies indicated that antibodies directed against sialyl-Lewis
a
, sialyl-
Lewis
x
, and Lewis
b
 epitopes react with human ZP (22, 23). The anti-Lewis
b
 antibody blocked 
human sperm-ZP binding in the hemizona assay (22). Erythroagglutinating phytohemagglutin 
also binds to human ZP, indicating that bisecting type N-glycans are expressed on this matrix 
(24). However, the current results have established that only the sialyl-Lewis
x
 antigen is 
expressed at physico-chemically confirmable levels on ZP. Based on assessments of signal to 
noise for detected molecular and fragment ions, it was estimated that other antigens must be 
substantially less than 1% of the glycome. The biophysical analyses here confirm the 
expression of carbohydrate sequences. Antibodies and lectins are useful for detecting 
carbohydrate ligands once their existence is confirmed, but they would not detect the 
multivalent presentations of sialyl-Lewis
x
 and sialyl-Lewis
x
-Lewis
x
 sequences.  
Little is known about how human spermatozoa bind to eggs. The work described here 
provides insight to the key binding interactions that are essential for natural human 
fertilization, supporting the hypothesis that human gamete binding primarily involves the 
participation of the selectin ligand sialyl-Lewis
x
. Since human spermatozoa do not express 
selectins (25), the major egg binding protein is very likely a lectin with a binding specificity 
that overlaps with the selectins.   
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Fig. 1. MALDI-TOF profiling of human ZP N- and O-glycans. (A) MALDI-TOF mass 
spectrum of N-glycans of human ZP. The upper panel covers the m/z range from 2,700- 
4,500 and the lower, overlapping, panel spans m/z 4,200-5,800. Each panel was normalised 
so that the most abundant peak is 100% intensity. Structural assignments were based on 
compositions assigned from molecular weights, complemented by MS/MS information and 
the results of the neuraminidase digest (Fig. S2). Where more than one structure is shown, the 
upper structure is the more abundant. Grey structures have antennae carrying 2-6 sialic acid. 
All the other glycans are exclusively 2-3 sialylated (yellow = bi-antennary; green = tri-
antennary; pink = tetra-antennary).  
 
Fig. 2. Partial MALDI-TOF-TOF fragment ion spectra obtained after collisional activation of 
the molecular ion at m/z 5733 in Fig. 1 and, m/z 4288 in Fig. S1, (upper and lower panels, 
respectively), illustrating how the fragment ions arising from loss of antennae in sialylated and 
desialylated samples, respectively, defined the antennae sequences. A minus refers to the loss 
of the designated antenna from molecular ion, Isomeric glycans were identified, which differ in 
fucose location (see cartoons on lower panel).   
  
Fig. 3. Structures of the core fucosylated, multivalent sialy-Lewis
x
 members of each of the bi-, 
tri- and tetra-antennary families (shaded yellow, green and pink, respectively) that were found 
on human ZP.  
 
Fig. 4. Sialyl-Lewis
x
 is involved in sperm-ZP binding. (A) Comparison of hemizona binding 
index (HZI) of capacitated spermatozoa incubated in the presence of sialyl-Lewis
x
 (SLEX), 
Lewis
x
 (LEX) and sialyl-N-acetyllactosamine (SLN) oligosaccharide or their BSA conjugates 
with medium alone (control).  Each point represents the mean±SEM of the results of 10 
hemizona assays.  *p<0.05 when compared to the corresponding untreated control. †p<0.05 
when compared with the desialylated counterpart. (B) Representative fluorescent images of 
capacitated spermatozoa incubated with Alexa Fluor-594 labeled sialyl-Lewis
x
-BSA. N=5. 
(C) Immunostaining of sialyl-Lewis
x
 sequences on hemizona. Matching hemizona were 
incubated with anti-sialyl-Lewis
x
 (CSLEX1) or anti-6-sulfo lacNAc sequences on extended 
core 1 O-glycans (MECA-79) or anti-Lewis
x
 antibodies or preabsorbed antibodies. N=5. (D) 
Effect of CSLEX1 and anti-Lewis
x
 antibody on sperm-ZP binding in hemizona binding 
assays. Matching hemizona were incubated with the antibodies or preabsorbed antibody as 
outlined in the Methods supplement. N=5. *p<0.05 when compared with the control. (E) 
Left: Effect of desialylation of solubilized ZP (1 μg/ml) on sperm-ZP binding in hemizona 
binding assays. N=5. Right: Representative photographs of the binding of native or 
desialylated ZP to spermatozoa.  
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Materials and Methods 
 
Purification of solubilized zona pellucida  
Unfertilized oocytes were obtained from the assisted reproduction program at Queen 
Mary Hospital, Hong Kong. The protocol of the study was approved by the Institutional 
Review Board of the University of Hong Kong/Hospital Authority Hong Kong West 
Cluster. Informed consent was obtained from patients donated their oocytes for the study.  
The purification of solubilized ZP was performed as described (21). Briefly, the 
purification involved the isolation of the ZP from the oocytes under a dissection 
microscope. The ZPs were then washed and heat-solubilized at 70°C in 5 mM NaH2PO4 
buffer (pH 2.5) for 90 minutes. 
 
Semen samples  
Informed consent was obtained from male donors for semen collection. The protocol 
for this collection was approved by the Institutional Review Board of the University of 
Hong Kong/Hospital Authority Hong Kong West Cluster. Spermatozoa from normal 
semen were processed by density gradient centrifugation on Percoll (Pharmacia, Uppsala, 
Sweden) (26, 27). After capacitation in Earle’s balanced salt solution (EBSS; Flow 
Laboratories, Irvine, UK) supplemented with sodium pyruvate, penicillin-G, streptomycin 
sulfate, and 3% bovine serum albumin for 3 hours, the spermatozoa were resuspended in 
EBSS containing 0.3% BSA (EBSS/BSA).  
 
Proteomics analysis  
NanoLC was performed on an nanoACQUITY UPLC System (Waters, Milford, 
USA) coupled to an LTQ-Orbitrap Velos hybrid mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) equipped with a PicoView nanospray interface (New 
Objective, Woburn, USA). Peptide mixtures were loaded onto a 75-μm × 250-mm 
nanoACQUITY UPLC BEH130 column packed with C18 resin (Waters, Milford, USA) 
and were separated at a flow rate of 300 nl/min using a linear gradient of 5 to 40% 
solvent B (95% acetonitrile with 0.1% formic acid) in 30 min, followed by a sharp 
increase to 85% B in 1 min and held at 85% B for another 10 min. Solvent A was 0.1% 
formic acid in water. The mass spectrometer was operated in the data-dependent mode. 
Briefly, survey full-scan MS spectra were acquired in the Orbitrap (m/z 350–1600) with 
the resolution set to 60,000 at m/z 400 and automatic gain control target at 106. The 20 
most intense ions were sequentially isolated for CID MS/MS fragmentation and detection 
in the linear ion trap (automatic gain control target at 5000) with previously selected ions 
dynamically excluded for 90 s. Ions with single and unrecognized charge states were also 
excluded. All the measurements in the Orbitrap were performed with the lock mass 
option for internal calibration. 
All MS and MS/MS raw data were processed by Raw2MSM and searched against 
all entries in Swissprot database (vr 2010_11), or only the human subset in taxonomy, 
using the Mascot Daemon 2.2 server, with the target-decoy database search option 
enabled. Search criteria used were: trypsin digestion; variable modifications set as 
carbamidomethylation (Cys), oxidation (Met) and deamidation (NQ); up to two missed 
cleavages allowed; and mass accuracy of 10 ppm for the parent ion and 0.60 Da for the 
fragment ions. Returned peptide hits were further filtered by the built-in Percolator 
scoring option with significant threshold set at p < 0.01 (peptide ion score > 20), which 
resulted in a zero peptide false discovery rate. 
 
Glycan sequencing by MALDI-TOF and MALDI-TOF/TOF 
Purified human ZP were digested using trypsin (Sigma) and purified by reverse-
phase Sep-Pak C18 cartridge (Waters Corp) as described (28). The N-glycans were then 
released by N-glycosidase F (Roche Applied Science) and purified on a Sep-Pak C18 
cartridge. The purified native N-glycans were permethylated as described (29), purified 
using a Sep-Pak C18 cartridge, dissolved in methanol and mixed with 20 mg/mL 2,5-
dihydrobenzoic acid in 70% methanol at a 1:1 ratio (v/v). The glycan-matrix mixture (1 
L) was spotted on a stainless steel target plate and dried in vacuum. MALDI-TOF and -
TOF/TOF data were obtained using a 4800 MALDI-TOF/TOF mass spectrometer (AB 
Sciex UK Limited).  Argon was used as the collision gas with collision energy of 1 kV. 
The MS and MS/MS data obtained were analyzed using Data Explorer 4.9. The 
assignment of glycan sequence was done by manual annotation informed by knowledge 
of human biosynthetic pathways. 
 
MALDI-MS screening of sulfated glycans  
A portion of the released native N-glycans was additionally permethylated using the 
NaOH/dimethyl sulfoxide slurry method for 3 h at 4˚C, followed by careful neutralization 
with 5% aqueous acetic acid on ice and then applied directly to a pre-washed and 
equilibrated C18 Sep-Pak cartridge (Waters), as described (29). For MALDI-MS 
analyses, the permethylated sample was redissolved in acetonitrile and mixed 1:1 with a 
3,4-diaminobenzophenone matrix solution (10 mg/ml in 75% acetonitrile/0.1% 
trifluoroacetic acid) (Acros Organics) for spotting onto the MALDI target plate. MALDI-
TOF MS analyses in negative ion mode were performed on a 4700 Proteomics Analyzer 
(Applied Biosystems), operated in the reflectron mode. 
 
Determination of acrosomal status and motility of spermatozoa 
Fluorescein isothiocyanate labeled peanut (Pisum sativum) agglutinin (FITC-PSA; 
Sigma) and Hoechst staining techniques were used to determine the acrosome reaction of 
spermatozoa (30). The fluorescence patterns of 300 spermatozoa in randomly selected 
fields were determined under a fluorescence microscope (Zeiss) with 400x magnification. 
Hobson Sperm Tracker System (Hobson Tracking Systems Ltd) was used to determine 
the motility of spermatozoa. The procedures and the set-up parameters of the system were 
described elsewhere (31).  
 
Hemizona binding assay 
The hemizona binding assay was performed as described previously (32). 
Unfertilized oocytes were micro-bisected into two identical hemizonae by a 
micromanipulator. Each hemizona was incubated with 2106 capacitated spermatozoa/ml 
in a 100 l droplet of EBSS/BSA for 3 hours at 37C in an atmosphere of 5% CO2 in air 
under mineral oil. The numbers of tightly bound spermatozoa on the outer surface of the 
hemizonae were counted. The hemizona binding index (HZI) was defined as the ratio of 
the number of bound spermatozoa in the test droplet to that in the control droplet times 
100.  
 
Effects of sialyl-Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-acetyllactosamine neoglycoprotein 
and sialyl-Lewis
x
/Lewis
x
/sialyl-N-acetyllactosamine oligosaccharide  
Hemizona binding assay were performed as described (31) in the presence of 
different concentrations of sialyl-Lewis
x
/Lewis
x
/sialyl-N-acetyllactosamine 
neoglycoprotein (0.01-2 µM) or sialyl-Lewis
x
/Lewis
x
/sialyl-N-acetyllactosamine 
oligosaccharide (Dextra; 0.1-500 µM) to determine their effects on the ZP binding 
capacity of capacitated spermatozoa. The effect of the neoglycoprotein and 
oligosaccharide on the acrosomal status, motility and viability of spermatozoa were also 
determined as described above. 
The binding of sialyl-Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-acetyllactosamine-BSA to 
capacitated spermatozoa and hemizona was visualized by cytochemical staining. Sialyl-
Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-acetyllactosamine-BSA (Dextra) was fluorescently 
labeled with Alexa Fluor-594 microscale fluorescence labeling kit (Invitrogen) according 
to the manufacturer's
 
protocol. Motile processed spermatozoa (2×10
6
 spermatozoa/ml) or 
hemizona were incubated with 0.5 M Alexa Fluor-594-labeled sialyl-Lewisx-
BSA/Lewis
x
-BSA/sialyl-N-acetyllactosamine-BSA in an atmosphere of 5% CO2 in air at 
37°C for
 
240 minutes. The treated spermatozoa or hemizona were washed with PBS 
containing 0.1% Triton-X 100 and examined under a phase-contrast microscope. 
Spermatozoa or hemizona incubated with labeled BSA were used as control. Image 
analysis was performed using Image-Pro Plus (Media Cybernetics). 
 
Effects of anti-sialyl-Lewis
x
 and Lewis
x
 antibodies 
For immunostaining, hemizona were incubated with 0.2 µg/ml of mouse monoclonal 
anti-sialyl-Lewis
x
 or anti-Lewis
x
 antibody (BD) for 3 hours at 37C. Three anti-sialyl-
Lewis
x
 antibodies with different specificities were used: CSLEX1 binds sialyl-Lewis
x
 but 
not 6-sulfo sialyl-Lewis
x
, MECA-79 only binds to 6-sulfo lacNAc on extended core 1 O-
glycans and HECA-452 binds both sialyl-Lewis
x
 and 6-sulfo sialyl-Lewis
x
 (33). 
Matching hemizona treated with irrelevant antibody or antibody preabsorbed by the 
addition of 1:100 sialyl-Lewis
x
-BSA or Lewis
x
-BSA were used as controls. Bound 
antibodies were detected by Alexa Fluor-594-conjugated goat anti-mouse IgG or anti-rat 
IgM (Invitrogen).   
To determine the effect of antibodies on the ZP binding capacity of capacitated 
spermatozoa, matching hemizona were pre-incubated either in various concentrations 
(0.1-10 µg/ml) of anti-sialyl-Lewis
x
 (CSLEX1)/Lewis
x
 antibody or preabsorbed antibody 
at 37C for 3 hours. The hemizona were then washed with fresh EBSS/BSA. The 
hemizona binding assays were performed on these treated hemizona as described (32).  
 
 
Binding of solubilized zona pellucida to spermatozoa 
Solubilized ZP was desialylated by incubation with sialidase coated agarose beads 
(Sigma) in 1M Tris-HCl (pH 7) at 37
 C for 18 hours (34). The free sialic acid produced 
was removed by dialysis with 2 mM Tris-HCl, pH 7.5 at 4C. The success of 
desialylation was verified by the decreased binding of the treated solubilized ZP to wheat 
germ agglutinin which binds strongly to sialylated glycans and weakly to other 
glycoconjugates. Both native and desialylated solubilized ZP were fluorescently labeled 
with Alexa Fluor-488 microscale fluorescence labeling kit (Invitrogen). 
The binding of native or desialylated solubilized ZP to spermatozoa was performed 
as described (35). Capacitated spermatozoa (2×10
6
/ml) were mildly fixed in 0.5% 
paraformaldehyde for 10 minutes at room temperature and washed followed by the 
incubation with 1 μg/ml solubilized ZP at 4C with slow shaking. After 24 hours, the 
spermatozoa were washed and the fluorescent signals were quantified using a microplate 
reader (Dynatech MR5000, Dynatech Laboratories). The results were expressed as 
percentage of fluorescence intensity relative to the control using native ZP. 
 
Data Analysis 
All the data were expressed as mean  standard error of the mean (SEM). The data 
were analyzed by statistical software packages (SigmaPlot 8.02 and SigmaStat 2.03, Jandel 
Scientific). For all experiments, the non-parametric repeated measures ANOVA on Rank 
test for multiple comparisons were used. If the data were normally distributed, Tukey 
Test or Parametric Student t-test was used where appropriate as the post-test. A probability 
value p<0.05 was considered to be statistically significant. 
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Fig. S1. MALDI-TOF-TOF fragment ion spectra obtained after collisional activation of 
(A) m/z 3664 and (B) m/z 4114 from the desialylated N-glycan sample (see Fig. S2 for 
MS data), and (C) m/z 4575 from the sialylated N-glycan sample (see Fig. 1a for MS 
data). These data complement the spectra shown in Fig. 2, further illustrating how the 
fragment ions define the antennae sequences. The cartoons show the sites of 
fragmentation within the antennae and the horizontal green arrows show the moieties 
which are liberated from the molecular ion when each of the fragment ions is formed. 
Note the diagnostic fragment ions at m/z 3458 (panel A) and 3908 (panel B) which arise 
specifically from elimination of the 3-linked fucose. 
Fig. S2 
 
 
Fig. S2 MALDI-TOF mass spectrum of N-glycans after 2-3-specific sialidase digestion. 
Glycans shaded grey have 2-6 sialylated antennae. All sialyl-LewisX antennae observed in 
Fig. 1 have been converted to Lewis
X
 by the sialidase (see annotations).  
 
 
Fig. S3 
 
 
Fig. S3.  Identification of sulfated N-glycans in the human ZP sample. A portion of the 
released N-glycans was taken through permethylation and screened by MALDI-MS in 
negative ion mode for the presence of sulfated glycans as described (15). No significant 
peak was observed initially but several weak signals were detected and could be assigned 
as annotated if the sample was first desialylated to reduce the heterogeneity. The 
desialylated, sulfated N-glycans thus identified correspond in composition to the 
desialylated, sulfated counterparts of those multiantennary structures carrying multiple 
sialyl Lewis
x
 epitopes which are shown in Fig. 1. 
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Fig. S4.  O-glycans found on human ZP. (A) MALDI-TOF mass spectrum of O-glycans 
obtained from reductive elimination of residual glycopeptides remaining after N-glycan 
release from trypsinised human ZP. Glycans were permethylated prior to MS analysis. 
Structural assignments take into account compositions assigned from molecular weights 
together with MS/MS-derived sequence information. Unlabelled signals are from the 
matrix used in the MALDI experiment. (B) Structures of O-glycans found on human ZP. 
Fig. S5 
 
 
 
 
 
 
 
 
 
 
Fig. S5. No immunoreactivity was observed on ZP using MECA-79 and anti-Lewis
x
 
antibodies. Matching hemizona were incubated with 0.2 µg/ml anti-6-sulfo sialyl-Lewis
x
 
(MECA-79) or anti-Lewis
x
 antibodies or antibodies preabsorbed with irrelevant antibody 
or Lewis
x
-BSA for 3 hours at 37ºC. The immunoreactivites were visualized using Alexa 
Fluor 594-conjugated goat anti-mouse IgG or anti-rat IgM. The results shown are 
representative of 5 replicate experiments. LEX: Lewis
x
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Fig. S6. Sialyl-Lewis
x
, but not Lewis
x
 and sialyl-N-acetyllactosamine, is involved in 
sperm-ZP binding. Representative photographs of ten replicate experiments showing the 
binding of capacitated spermatozoa to hemizona in the presence of Sialyl-Lewis
x
-BSA, 
Lewis
x
-BSA and sialyl-N-acetyllactosamine-BSA neoglycoprotein or alternatively Sialyl-
Lewis
x
, Lewis
x
 and sialyl-N-acetyllactosamine-BSA oligosaccharide with medium alone 
(control). SLEX: Sialyl Lewis
x
; LEX: Lewis
x
; SLN: sialyl-N-acetyllactosamine. 
Fig. S7 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S7. Fluorescently labeled sialyl-Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-
acetyllactosamine-BSA did not bind to ZP. Matching hemizona were incubated with 0.5 
µM Alexa-594 conjugated sialyl-Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-acetyllactosamine-
BSA or BSA for 240 minutes at 37ºC. Fluorescently-labeled sialyl Lewis
x
/Lewis
x
-
BSA/sialyl-N-acetyllactosamine-BSA and BSA did not bind to the hemizona. The results 
shown are representative of 5 replicate experiments. SLEX: Sialyl Lewis
x
; LEX: Lewis
x
; 
SLN: sialyl-N-acetyllactosamine. 
Alexa-594 Phase contrast Alexa-594 Phase contrast 
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Supplementary Fig. S8. Fluorescently labeled sialyl-Lewis
x
-BSA/Lewis
x
-BSA/sialyl-N-
acetyllactosamine-BSA did not bind to capacitated spermatozoa. Representative 
fluorescent images of capacitated spermatozoa incubated with 0.5 µM Alexa Fluor-594 
labeled sialyl-Lewis
x
-BSA, Lewis
x
-BSA, sialyl-N-acetyllactosamine-BSA or BSA for 
240 minutes at 37ºC. The results shown are representative of 5 replicate experiments. 
SLEX: Sialyl Lewis
x
; LEX: Lewis
x
; SLN: sialyl-N-acetyllactosamine 
Alexa-594 Phase contrast 
Fig. S9 
 
 
 
 
 
 
 
 
 
 
 
A 
Treatment 
Sperm motility parameters 
VAP 
(µm/s) 
VCL 
(µm/s) 
VSL 
(µm/s) 
BCF 
(Hz) 
ALH 
(µm) 
LIN 
(%) 
STR 
(%) 
HYP 
(%) 
Progressive 
 Motility (%) 
Control 54.6  2.3 80.1  4.0 42.4  2.7 10.4  1.4 7.0  1.0 53.4  3.8 78.2  6.2 6.6  1.5 48.2  4.3 
Neoglycoprotein 
SLEX-BSA 57.6  2.0 79.9  5.7 40.4  2.7 10.4  0.8 7.0  1.1 50.8  2.0 70.4  4.9 6.4  1.2 55.6  3.3 
LEX-BSA 50.8  3.0 79.6  3.5 42.2  3.4 10.6  1.6 9.6  1.4 53.6  5.4 83.0  4.3 7.8  1.9 56.4  3.9 
SLN-BSA 50.2  2.2 73.2  3.8 41.0  4.2 10.0  0.7 7.6  1.6 57.4  8.3 81.8  7.2 9.2  2.4 47.9  5.9 
Oligosaccharide 
SLEX 55.6  3.0 76.7  4.5 39.0  2.0 9.2  1.5 8.6  1.5 50.8  1.6 71.1  6.1 8.0  3.0 56.7  4.4 
LEX 53.6  3.0 78.6  4.3 41.5  3.7 9.0  0.8 8.4  1.2 53.4  6.3 79.8  12.0 8.0  0.7 55.4  4.1 
SLN 54.0  4.6 77.8  5.9 40.8  4.9 9.8  0.8 8.6  1.5 53.4  7.8 79.4  13.2 7.4  0.8 50.6  2.9 
 
B 
Neoglycoprotein Oligosaccharide 
  
 
Fig. S9. Sialyl Lewis
x
/Lewis
x
/sialyl-N-acetyllactosamine-BSA and sialyl 
Lewis
x
/Lewis
x
/sialyl-N-acetyllactosamine oligosaccharides have no effect on the 
acrosomal status and motility parameters of human spermatozoa. (A) The effect of 
neoglycoproteins (0.01-2 μM) and oligosaccharides (0.1-500 μM) on the acrosomal status 
of spermatozoa. The fluorescence patterns of 300 fluorescein isothiocyanate-labeled 
Pisum sativum agglutinin-treated spermatozoa in randomly selected fields were 
determined. Data represent mean ± SEM of 5 separate experiments. (B) The effect of 
neoglycoproteins (2 μM) and oligosaccharides (500 μM) on motility were determined 
Hobson Sperm Tracker System. Parameters of spermatozoan motility measured: average 
path velocity (VAP), curvilinear velocity (VCL), straight line velocity (VSL), beat cross 
frequency (BCF), amplitude of lateral head displacement (ALH), linearity (LIN; 
VSL/VCL), straightness (STR; VSL/VAP), percentage hyperactivation (HYP; VCL ≥ 
100 μm/s, LIN ≤ 60% and ALH ≥ 5.0 μm) and percentage progressive motility (VAP ≥ 
25 μm/s). Data represent the mean ± SEM of five separate experiments using 5 different 
samples of spermatozoa. SLEX: Sialyl Lewis
x
; LEX: Lewis
x
; SLN: sialyl-N-
acetyllactosamine. 
  
 
Fig. S10 
 
 
 
 
 
 
 
 
Fig. S10. Representative photographs of binding of spermatozoa to hemizona following 
incubation with anti-sialyl-Lewis
x
 or Lewis
x
 antibody. Matching hemizona were incubated 
with the 10 μg/ml anti-sialyl-Lewisx (CSLEX1)/Lewisx antibody or preabsorbed antibody 
antibodies at 37C for 3 hours.. The results shown are representative of 5 replicate 
experiments.  
 
 
 
 
 
 
  
 
 
Table S1.   
  Protein description 
protein 
score 
% 
protein 
coverage 
charge 
state 
peptide mw 
(theoretical) 
peptide 
score 
peptide sequence peptide modifications 
         
1 Zona pellucida sperm-binding 
protein 4 
1023 32.8 2 1096.5699 68.73 LPCAPSPISR Carbamidomethyl (C) 
   2 1101.5567 38.33 EGHFSIAVSR  
    2 1263.6459 152.61 AVYENELVATR  
    2 1410.7718 48.33 NVTSPPLLLDSVR Deamidated (NQ) 
    2 1439.7773 140.53 DPIYVEVSILHR  
    3 1439.7773 44.45 DPIYVEVSILHR  
    2 1617.6729 53.82 DAPDTDWCDSIPAR Carbamidomethyl (C) 
    2 1679.7831 70.34 NYGSYYGVGDYPVVK  
    2 1761.8978 152.61 FSIFTFSFVNPTVEK  
    2 2093.0252 152.61 GCPYIGDNYQTQLIPVQK Carbamidomethyl (C) 
    4 3248.4836 77.07 GPVHLHCSVSVCQPAETPSCVVTCPDLSR 4 Carbamidomethyl (C) 
    3 3248.4836 152.61 GPVHLHCSVSVCQPAETPSCVVTCPDLSR 4 Carbamidomethyl (C) 
    3 3547.3844 44.05 GDCEGLGCCYSSEEVNSCYYGNTVTLHCTR 5 Carbamidomethyl (C) 
         
2 Haptoglobin 815 38.4 2 919.4552 61.88 GSFPWQAK  
    2 979.4876 145.46 VGYVSGWGR  
    2 1202.6295 152.61 VTSIQDWVQK  
    2 1344.6384 56.31 SCAVAEYGVYVK Carbamidomethyl (C) 
    2 1438.6576 46.17 TEGDGVYTLNNEK  
    2 1459.6943 26.55 NLFLNHSENATAK 2 Deamidated (NQ) 
    2 1722.8069 26.04 YVMLPVADQDQCIR Carbamidomethyl (C) 
Oxidation (M) 
    3 1794.0040 51.14 VVLHPNYSQVDIGLIK  
    3 1856.9124 144.1 AVGDKLPECEAVCGKPK 2 Carbamidomethyl (C) 
    2 2187.0453 152.61 SPVGVQPILNEHTFCAGMSK Carbamidomethyl (C) 
Oxidation (M) 
    3 2695.3639 152.61 MVSHHNLTTGATLINEQWLLTTAK Deamidated (NQ) 
Oxidation (M) 
         
3 Zona pellucida sperm-binding 
protein 2 
780 19.9 2 992.4597 32.62 VMNNSAALR 2 Deamidated (NQ) 
Oxidation (M) 
    2 1114.5117 56.69 DFMSFSLPR Oxidation (M) 
  
 
  Protein description 
protein 
score 
% 
protein 
coverage 
charge 
state 
peptide mw 
(theoretical) 
peptide 
score 
peptide sequence peptide modifications 
    3 1271.6081 57.08 FHIPLNGCGTR Carbamidomethyl (C)  
Deamidated (NQ) 
    2 1390.6980 34.6 EITVEFPSSPGTK  
    2 1519.7089 53.94 VQMGWSIEVGDGAR Oxidation (M) 
    2 1860.8710 152.61 LSPDSPLCSVTCPVSSR 2 Carbamidomethyl (C) 
    2 2169.1351 152.61 NDMLLNINVESLTPPVASVK Oxidation (M) 
    3 2786.2932 152.61 WHASVVDPLGLDMPNCTYILDPEK Carbamidomethyl (C)  
Deamidated (NQ) 
Oxidation (M) 
    3 3402.6298 115.11 VIFSSQAICAPDPVTCNATHMTLTIPEFPGK 2 Carbamidomethyl (C)  
Deamidated (NQ) 
         
4 Transthyretin  658 55.1 2 1365.7517 152.61 GSPAINVAVHVFR  
    2 2359.2311 152.61 YTIAALLSPYSYSTTAVVTNPK  
    3 2450.1979 26 ALGISPFHEHAEVVFTANDSGPR  
    2 2454.1438 152.61 TSESGELHGLTTEEEFVEGIYK  
    2 2488.2737 152.61 YTIAALLSPYSYSTTAVVTNPKE  
         
5 Zona pellucida sperm-binding 
protein 3 
586 17.2 2 1278.5550 133.46 LMEENWNAEK Oxidation (M) 
   2 1470.7202 152.61 VTLAEQDPDELNK  
    2 2603.2095 152.61 AADLTLGPEACEPLVSMDTEDVVR Carbamidomethyl (C) 
Oxidation (M) 
    2 2603.2095 74.5 AADLTLGPEACEPLVSMDTEDVVR Carbamidomethyl (C) 
Oxidation (M) 
    3 3035.2670 152.61 ACSFSKPSNSWFPVEGSADICQCCNK 4 Carbamidomethyl (C) 
             
6 Zona pellucida sperm-binding 
protein 1 
570 14.1 2 1611.8257 152.61 FTVATFALLDSGSQR  
   2 1963.8557 143.56 EVPCYYGNTATVQCFR 2 Carbamidomethyl (C) 
    3 1980.9939 50.64 VDVAQDATLICPKPDPSR Carbamidomethyl (C) 
    2 2054.8745 152.61 DETFSSYYGEDDYPIVR  
    3 2767.3170 150.92 DYIGTHLSQEQCQVASGHLPCIVR 2 Carbamidomethyl (C) 
         
7 Hemopexin 483 15.6 2 1404.6456 143.71 SWPAVGNCSSALR Carbamidomethyl (C)  
Deamidated (NQ) 
    2 1494.6714 109.15 YYCFQGNQFLR Carbamidomethyl (C) 
    2 1499.6755 100.67 EWFWDLATGTMK Oxidation (M) 
    2 1711.7624 72.32 GECQAEGVLFFQGDR Carbamidomethyl (C) 
    2 2363.1580 136.94 LLQDEFPGIPSPLDAAVECHR Carbamidomethyl (C) 
         
  
 
  Protein description 
protein 
score 
% 
protein 
coverage 
charge 
state 
peptide mw 
(theoretical) 
peptide 
score 
peptide sequence peptide modifications 
8 Afamin 455 10 2 1589.8202 84.13 ESLLNHFLYEVAR  
    2 1621.6930 152.61 AESPEVCFNEESPK Carbamidomethyl (C) 
    2 1712.9196 152.61 IAPQLSTEELVSLGEK  
    2 1886.9302 73.35 SDVGFLPPFPTLDPEEK  
         
9 Zinc-alpha-2-glycoprotein 174 9.4 2 1450.6762 81.3 AYLEEECPATLR Carbamidomethyl (C) 
    2 1781.9352 112.24 EIPAWVPFDPAAQITK  
         
10 Ferritin light chain 153 8.6 2 1606.7991 152.61 LGGPEAGLGEYLFER  
         
11 Alpha-1-acid glycoprotein 1 153 7 2 1741.7981 152.61 EQLGEFYEALDCLR Carbamidomethyl (C) 
         
12 Alpha-1B-glycoprotein 153 3.4 2 1874.9924 152.61 VTLTCVAPLSGVDFQLR Carbamidomethyl (C) 
         
13 Major vault protein 134 1.8 2 1814.9454 133.87 LAQDPFPLYPGEVLEK  
         
14 Alpha-1-antitrypsin 123 4.3 2 1833.8996 122.61 VFSNGADLSGVTEEAPLK Deamidated (NQ) 
         
15 N-acetylmuramoyl-L-alanine 
amidase 
117 2.3 2 1491.7028 117.27 TDCPGDALFDLLR Carbamidomethyl (C) 
         
16 Prostaglandin-H2 D-isomerase 105 10 2 1919.0000 105.34 SVVAPATDGGLNLTSTFLR Deamidated (NQ) 
         
17 Polyubiquitin-B 105 7 2 1786.9200 105.17 TITLEVEPSDTIENVK  
         
18 MAP kinase-activating death 
domain protein 
50 3.3 4 6132.2975 49.71 VDIEVLPQELQPALTFALPDPSRFTLVDFPLHLP 
LELLGVDACLQVLTCILLEHK 
Deamidated (NQ) 
         
19 Trypsin-1  38 4 2 1191.6057 38.37 TLNNDIMLIK 2 Deamidated (NQ) 
Oxidation (M) 
         
20 Peripheral plasma membrane 
protein CASK 
36 1.2 2 1298.6223 36.27 MNELNHCIVAR  
         
21 Hemoglobin subunit beta 26 6.8 2 1273.7183 26.15 LLVVYPWTQR  
             
 
  
 
Table S1.  Shotgun proteomic analysis of the purified human ZP sample. The protein band corresponding to the purified human 
ZP sample was subjected to in-gel tryptic digestion and extracted peptides were further de-N-glycosylated by PNGase F prior to LC-
MS/MS analysis under data dependent acquisition mode. Full experimental conditions and peptide identification criteria were as 
described in Methods. 
 
